These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 18006540)

  • 1. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity.
    Halvorsen EH; Pollmann S; Gilboe IM; van der Heijde D; Landewé R; Ødegård S; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2008 Mar; 67(3):414-7. PubMed ID: 18006540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate.
    Pollmann S; Stensland M; Halvorsen EH; Sollid LM; Kvien TK; Fleckenstein B; Molberg O
    Rheumatol Int; 2012 May; 32(5):1271-6. PubMed ID: 21267570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis.
    Zhao J; Zhao Y; He J; Jia R; Li Z
    J Rheumatol; 2008 Jun; 35(6):969-74. PubMed ID: 18398945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
    Umeda N; Matsumoto I; Kawaguchi H; Kurashima Y; Kondo Y; Tsuboi H; Ogishima H; Suzuki T; Kagami Y; Sakyu T; Ishigami A; Maruyama N; Sumida T
    Clin Rheumatol; 2016 May; 35(5):1181-8. PubMed ID: 26415740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.
    van Gaalen FA; van Aken J; Huizinga TW; Schreuder GM; Breedveld FC; Zanelli E; van Venrooij WJ; Verweij CL; Toes RE; de Vries RR
    Arthritis Rheum; 2004 Jul; 50(7):2113-21. PubMed ID: 15248208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies.
    Jaskowski TD; Hill HR; Russo KL; Lakos G; Szekanecz Z; Teodorescu M
    J Rheumatol; 2010 Aug; 37(8):1582-8. PubMed ID: 20516016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two novel sandwich ELISAs identify PAD4 levels and PAD4 autoantibodies in patients with rheumatoid arthritis.
    Ishigami A; Uchida Y; Miyazaki T; Handa S; Choi EK; Kim YS; Kasahara Y; Maruyama N
    Mod Rheumatol; 2013 Jul; 23(4):794-803. PubMed ID: 22986904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.
    Xue Y; Zhang J; Chen YM; Guan M; Zheng SG; Zou HJ
    Scand J Rheumatol; 2008; 37(3):183-7. PubMed ID: 18465452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-citrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity.
    Umeda N; Matsumoto I; Ito I; Kawasaki A; Tanaka Y; Inoue A; Tsuboi H; Suzuki T; Hayashi T; Ito S; Tsuchiya N; Sumida T
    Clin Exp Immunol; 2013 Apr; 172(1):44-53. PubMed ID: 23480184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
    Berglin E; Johansson T; Sundin U; Jidell E; Wadell G; Hallmans G; Rantapää-Dahlqvist S
    Ann Rheum Dis; 2006 Apr; 65(4):453-8. PubMed ID: 16176994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus.
    Popescu C; Zofotă S; Bojincă V; Ionescu R
    Rom J Intern Med; 2013; 51(3-4):179-87. PubMed ID: 24620631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles.
    Snir O; Widhe M; von Spee C; Lindberg J; Padyukov L; Lundberg K; Engström A; Venables PJ; Lundeberg J; Holmdahl R; Klareskog L; Malmström V
    Ann Rheum Dis; 2009 May; 68(5):736-43. PubMed ID: 18635594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies.
    Jiang X; Trouw LA; van Wesemael TJ; Shi J; Bengtsson C; Källberg H; Malmström V; Israelsson L; Hreggvidsdottir H; Verduijn W; Klareskog L; Alfredsson L; Huizinga TW; Toes RE; Lundberg K; van der Woude D
    Ann Rheum Dis; 2014 Oct; 73(10):1761-8. PubMed ID: 24812286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis.
    Kobayashi T; Ito S; Kobayashi D; Shimada A; Narita I; Murasawa A; Nakazono K; Yoshie H
    PLoS One; 2016; 11(4):e0154182. PubMed ID: 27111223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis.
    Kapitány A; Szabó Z; Lakos G; Aleksza M; Végvári A; Soós L; Karányi Z; Sipka S; Szegedi G; Szekanecz Z
    Isr Med Assoc J; 2008 Jan; 10(1):32-6. PubMed ID: 18300568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of HLA-DRB1 alleles with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in northern east part of Turkey.
    Uçar F; Çapkin E; Karkucak M; Yücel B; Sönmez M; Alver A; Kaklikkaya N; Tosun M; Alemdaroğlu E; Solak M
    Int J Rheum Dis; 2012 Dec; 15(6):538-45. PubMed ID: 23253237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.